SCHEMBL3204772

SCHEMBL3204772

CCOC(=O)CCc1cc(OC(C)C)n[nH]1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
P2RY12 Q9H244 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 2/20 0.36
HCAR2 Q8TDS4 4/20 0.36
KDM4E B2RXH2 4/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
HCAR3 P49019 2/20 0.35
PTPN1 P18031 1/20 0.34
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107095 0.81 PDE3B (0.40) CYP4F2CYP4A11ALDH1A1MAPTPDE3B
SCHEMBL3211090 0.81 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1MAPTPDE3B
SCHEMBL8009877 0.79 CYP4F2 (0.45) CYP4F2CYP4A11ALDH1A1MAPTPDE3B
SCHEMBL5599296 0.76 HCAR2 (0.65) HCAR2HCAR3
SCHEMBL8010853 0.76 PDE3B (0.39) CYP4F2CYP4A11ALDH1A1MAPTPDE3B
SCHEMBL5111818 0.74 ALPL (0.50) ALDH1A1MAPTSMN1; SMN2LMNAKDM4E
SCHEMBL27500020 0.72 CYP4F2 (0.48) CYP4F2CYP4A11PDE3BPDE3AP2RY12
SCHEMBL27430808 0.70 CYP4F2 (0.51) CYP4F2CYP4A11ALDH1A1PDE3BPDE3A
SCHEMBL3261435 0.70 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2LMNAHCAR2KDM4E
SCHEMBL27773485 0.69 CYP1A2 (0.44) CYP4F2CYP4A11ALDH1A1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
CN-101282725-A Therapeutic agent for diabetes TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2008-10-08 CN disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080051418-A1 Arylalkanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-28 US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
EP-1829863-A1 ARYLALKANOIC ACID DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-09-05 EP disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 CYP4F2 2195/4885CYP4A11 523/4885ALDH1A1 212/4885
US-20080051418-A1 Arylalkanoic Acid Derivative INSR, NPY1R, GPR119 CYP4F2 1398/4885CYP4A11 520/4885ALDH1A1 1527/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 CYP4F2 1094/4885CYP4A11 402/4885ALDH1A1 118/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 CYP4F2 2195/4885CYP4A11 523/4885ALDH1A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.